<p><a href="https://www.ncbi.nlm.nih.gov/gene/7468">NSD2</a> p.E1099K (EK) is a mutation shown to be enriched in patients that relapse with pediatric Acute Lymphoblastic Leukemia (ALL). This work aims to uncover 3D chromatin architecture-related mechanisms responsible for drug resistance or therapy failure in these patients. We investigated this by performing Hi-C, ATAC-Seq, and RNA-Seq on three B-ALL cell lines heterozygous for EK either expressing a <a href="https://www.ncbi.nlm.nih.gov/gene/7468">NSD2</a> targeting small RNA (sRNA) or a non-targeting small hairpin RNAs (shRNA). We also performed RNA-Seq on three matched diagnosis/relapse B-ALL samples with the relapse enriched EK mutation. </p>

NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by    Disrupting 3D Chromatin Organization

Precursor Cell Lymphoblastic Leukemia-Lymphoma study with RNA-Seq data on dbGaP (6 participants)

NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by Disrupting 3D Chromatin Organization

Description

Applying For Access

Summary